MARKETING OF ANTI-ULCER DRUGS TO THE END-USERS
HTML Full TextMARKETING OF ANTI-ULCER DRUGS TO THE END-USERS
Kanagala Anusha *, V Narasimha Rao and P. Vijaya Kumar
Prasad V. Potluri Siddhartha Institute of Technology, Kanuru, Andhra Pradesh, India
Akkineni Nageswara Rao College, Gudivada, Andhra Pradesh, India
School of Management Studies, JNTUK-Kakinada, Andhra Pradesh, India
ABSTRACT: The paper focuses on different marketing techniques in Pharmaceutical Industry with reference to anti-ulcer drugs. This is an industry where a number of characteristics like, efficacy, quality and safety matters while delivering a product (i.e. the drug). This study comes up with drug development and the various aspects of bringing the product to the market. Secondly, it deals with determining the relationship between type of anti-ulcer drug prescribed and various product related factors. Thirdly, it focuses on strategies required for establishing strong presence in the therapeutic category. Methods and Materials: Testing of hypothesis is conducted among the type of anti-ulcer drug prescribed and elements of the marketing mix. Result: The important elements in prescribing anti-ulcer drugs to patients are determined.
Keywords: |
Pharmaceuticals, Marketing Strategy, 4 P's involvement, End-users
INTRODUCTION: Ulcer: Ulcer is erosion or sore where tissue has been destroyed by the gastric juices and stomach acid. Usually, peptic ulcer occurs in the lining of the stomach or the duodenum 1. Ulcers are a very common condition seen throughout the world and in India. Millions of people are affected by the ulcers annually. The primary reason for the increase in number of patients affected by peptic ulcer are due to the Stress, lifestyle changes, alcohol consumption, smoking etc 2, 3. The major indication where anti-ulcer drug usage is seen is in critical care, during acute gastritis, for treating peptic ulcer, during gastro-oesophageal reflux and also for other treatments along with analgesics.
Anti-ulcers drugs are classified into proton-pump inhibitors, antacids, histamine antagonists, sucralfate and others 4, 5.
This paper reviews the marketing practices in the pharmaceutical sector, examining both the doctor and pharmacist oriented promotion. It presents the marketing practices and their impact on the doctors & pharmacists. It also, identifies the factors necessary for marketers in pharmaceutical sector in executing the best strategies for both the end-users prescribing anti-ulcer drugs 6.
The marketing mix elements in the pharmaceutical marketing are:
Pharmaceutical drugs are classified into three categories. They are branded, branded-generic and generic drugs. The branded and generic drugs will have the same active ingredient. And both pass the bio-equivalence tests 7. But still there is misconception that generic drugs are sub standard drugs both in doctors as well as in the minds of the patient 8, 9. The paper tests the association of the type of anti-ulcer drug and the elements of the marketing mix.
Objective of the study:
This study focuses on finding the important market related factors like product, price place and promotion. The research is done to find out the expectation of doctors and pharmacists from anti-ulcer drugs.
Hypothesis:
- There is no significant association between type of anti-ulcer drugs prescribed and the quality of ingredient
- There is no significant association between type of anti-ulcer drugs prescribed and product name.
- There is no significant association between type of anti-ulcer drugs prescribed and product attribute factors
- There is no significant association between type of anti-ulcer drugs prescribed and price.
- There is no significant association between type of anti-ulcer drugs prescribed and distribution.
- There is no significant association between type of anti-ulcer drugs prescribed and promotion.
Questionnaire:
After an extensive study of the available previous literature a questionnaire was developed. The responses were collected through Likert's scale of “Strongly Disagree - Strongly Agree” (5 point scale).1
Research sample:
The targeted sample is the doctors and pharmacists in the industry who prescribe anti-ulcer drugs. The doctors and pharmacists were approached via medical representatives. The target sample population consists of doctors of various specialities like general surgeon, general medicine and gastro enterologists etc.
Data collection:
The questionnaire was directly distributed and collected from the research sample and is entered into a spreadsheet and uploaded into SPSS tool. The questionnaire had a covering letter introducing and explaining the purpose of the research. The data was collected from 113 valid responses and have been analyzed through SPSS 17.
Reliability:
Reliability Statistics | ||
Profession | Cronbach's Alpha | N of Items |
Doctors | .832 | 9 |
Pharmacists | .523 | 9 |
Scale Statistics | ||||
Profession | Mean | Variance | Std. Deviation | N of Items |
Doctors | 34.23 | 16.487 | 4.060 | 9 |
Pharmacists | 35.03 | 4.654 | 2.157 | 9 |
Inference: Cronbach’s alpha has been run for to check their reliability profession wise. The above table displays some of the results obtained. The overall alpha values for the Doctors and Pharmacists of all items are 0.832 and 0.523 respectively; these values are very high and indicate strong internal consistency among the given items 11.
RESULT ANALYSIS:
Crosstabs:
Type of anti-ulcer drugs prescribed * factors influencing in choice of anti-ulcer drug on the basis quality of ingredient:
H0: There is no significant association between type of anti-ulcer drugs prescribed and the quality of ingredient
H1: There is a significant association between type of anti-ulcer drugs prescribed and the quality of ingredient.
TABLE: 1 RESPONDENT'S OPINION ON THE QUALITY OF INGREDIENT AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Crosstab | ||||||
Factors influencing in choice of anti-ulcer drug on the basis quality of ingredient | Total | |||||
Neutral | Agree | Strongly Disagree | ||||
Type of anti-ulcer drugs prescribed | Branded | Count | 11 | 49 | 12 | 72 |
% within Type of anti-ulcer drugs prescribed | 15.3% | 68.1% | 16.7% | 100.0% | ||
Branded Generic | Count | 11 | 13 | 4 | 28 | |
% within Type of anti-ulcer drugs prescribed | 39.3% | 46.4% | 14.3% | 100.0% | ||
Generic | Count | 4 | 8 | 1 | 13 | |
% within Type of anti-ulcer drugs prescribed | 30.8% | 61.5% | 7.7% | 100.0% | ||
Total | Count | 26 | 70 | 17 | 113 | |
% within Type of anti-ulcer drugs prescribed | 23.0% | 61.9% | 15.0% | 100.0% |
Chi-Square Tests | |||
Value | df | Asymp. Sig. (2-sided) | |
Pearson Chi-Square | 7.561a | 4 | .109 |
a. 3 cells (33.3%) have expected count less than 5. The minimum expected count is 1.96. |
From the above table chi square is not significant (sig. value is 0.109 which is greater than 0.05), no evidence to reject null hypothesis. It means that there is no significant association between type of anti-ulcer drugs prescribed and their opinions on factors are influencing to choose the anti-ulcer drug on the basis quality of ingredient 12.
Symmetric Measures | |||
Value | Approx. Sig. | ||
Nominal by Nominal | Phi | .259 | .109 |
Cramer's V | .183 | .109 | |
N of Valid Cases | 113 |
The strength of association between type of anti-ulcer drugs prescribed and their opinions on factors influencing in choice of the anti-ulcer drug on the basis quality of ingredient is 0.183
GRAPH 1: RESPONDENT'S OPINION ON THE QUALITY OF INGREDIENT AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Type of anti-ulcer drugs prescribed and product name factors:
H0: There is no significant association between type of anti-ulcer drugs prescribed and product name.
H1: There is a significant association between type of anti-ulcer drugs prescribed and product name 13.
TABLE 2: RESPONDENT'S OPINION ON PRODUCT NAME AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Crosstab | |||||||
Opinions of prescribing an anti-ulcer drug based on product name factors | Total | ||||||
Disagree | Neutral | Agree | Strongly Disagree | ||||
Type of anti-ulcer drugs prescribed | Branded | Count | 0 | 21 | 44 | 7 | 72 |
% within Type of anti-ulcer drugs prescribed | .0% | 29.2% | 61.1% | 9.7% | 100.0% | ||
Branded Generic | Count | 0 | 11 | 14 | 3 | 28 | |
% within Type of anti-ulcer drugs prescribed | .0% | 39.3% | 50.0% | 10.7% | 100.0% | ||
Generic | Count | 1 | 4 | 7 | 1 | 13 | |
% within Type of anti-ulcer drugs prescribed | 7.7% | 30.8% | 53.8% | 7.7% | 100.0% | ||
Total | Count | 1 | 36 | 65 | 11 | 113 | |
% within Type of anti-ulcer drugs prescribed | .9% | 31.9% | 57.5% | 9.7% | 100.0% |
Chi-Square Tests | |||
Value | df | Asymp. Sig. (2-sided) | |
Pearson Chi-Square | 8.896a | 6 | .179 |
a. 6 cells (50.0%) have expected count less than 5. The minimum expected count is .12. |
From the above table chi square is not significant (sig. value is 0.179 which is greater than 0.05), no evidence to reject null hypothesis. It means that there is no significant association between type of anti-ulcer drugs prescribed and their opinions on product name factors.
Symmetric Measures | |||
Value | Approx. Sig. | ||
Nominal by Nominal | Phi | .281 | .179 |
Cramer's V | .198 | .179 | |
N of Valid Cases | 113 |
The strength of association between type of anti ulcer drugs prescribed and their opinions on product name factors is 0.198.
Type of anti-ulcer drugs prescribed and product attribute factors: H0: There is no significant association between type of anti-ulcer drugs prescribed and product attribute factors.
H1: There is a significant association between type of anti-ulcer drugs prescribed and product attribute factors 14.
GRAPH 2: RESPONDENT'S OPINION ON PRODUCT NAME AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
TABLE 3: RESPONDENT'S OPINION ON PRODUCT ATTRIBUTE FACTORS AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Crosstab | ||||||
Opinions of prescribing an anti-ulcer drug based on product attribute factors | Total | |||||
Neutral | Agree | Strongly Disagree | ||||
Type of anti-ulcer drugs prescribed | Branded | Count | 11 | 43 | 7 | 61 |
% within Type of anti-ulcer drugs prescribed | 18.0% | 70.5% | 11.5% | 100.0% | ||
Branded Generic | Count | 12 | 12 | 4 | 28 | |
% within Type of anti-ulcer drugs prescribed | 42.9% | 42.9% | 14.3% | 100.0% | ||
Generic | Count | 9 | 3 | 1 | 13 | |
% within Type of anti-ulcer drugs prescribed | 69.2% | 23.1% | 7.7% | 100.0% | ||
Total | Count | 32 | 58 | 12 | 102 | |
% within Type of anti-ulcer drugs prescribed | 31.4% | 56.9% | 11.8% | 100.0% |
Chi-Square Tests | |||
Value | df | Asymp. Sig. (2-sided) | |
Pearson Chi-Square | 16.483a | 4 | .002 |
a. 3 cells (33.3%) have expected count less than 5. The minimum expected count is 1.53. |
From the above table chi square is significant (sig. value is 0.002 which is less than 0.05), reject null hypothesis. It means that there is a significant association between type of anti-ulcer drugs prescribed and their opinions choosing antiulcer drugs based on product attribute factors.
Symmetric Measures | |||
Value | Approx. Sig. | ||
Nominal by Nominal | Phi | .402 | .002 |
Cramer's V | .284 | .002 | |
N of Valid Cases | 102 |
The strength of association between type of anti-ulcer drugs prescribed and their opinions choosing antiulcer drugs based on product attribute factors is 0.284
GRAPH: 3 RESPONDENT'S OPINION ON PRODUCT ATTRIBUTE FACTORS AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Type of anti-ulcer drugs prescribed and price factors:
H0: There is no significant association between type of anti-ulcer drugs prescribed and their opinions on choosing an antiulcer drug from the following options in price factors
H1: There is a significant association between type of anti-ulcer drugs prescribed and their opinions on choosing an antiulcer drug from the following options in price factors.
TABLE 4: RESPONDENT'S OPINION ON PRICE AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Crosstab | |||||||
Opinions of prescribing an anti-ulcer drug based on price factors | Total | ||||||
Disagree | Neutral | Agree | Strongly Disagree | ||||
Type of anti-ulcer drugs prescribed | Branded | Count | 3 | 30 | 27 | 12 | 72 |
% within Type of anti-ulcer drugs prescribed | 4.2% | 41.7% | 37.5% | 16.7% | 100.0% | ||
Branded Generic | Count | 2 | 3 | 19 | 5 | 29 | |
% within Type of anti-ulcer drugs prescribed | 6.9% | 10.3% | 65.5% | 17.2% | 100.0% | ||
Generic | Count | 0 | 5 | 8 | 0 | 13 | |
% within Type of anti-ulcer drugs prescribed | .0% | 38.5% | 61.5% | .0% | 100.0% | ||
Total | Count | 5 | 38 | 54 | 17 | 114 | |
% within Type of anti-ulcer drugs prescribed | 4.4% | 33.3% | 47.4% | 14.9% | 100.0% |
Chi-Square Tests | |||
Value | df | Asymp. Sig. (2-sided) | |
Pearson Chi-Square | 13.436a | 6 | .037 |
a. 6 cells (50.0%) have expected count less than 5. The minimum expected count is .57. |
From the above table chi square is significant (sig. value is 0.037 which is less than 0.05), reject null hypothesis. It means that there is a significant association between type of anti-ulcer drugs prescribed and their opinions on choosing an antiulcer drug from the following options in price factors.
Symmetric Measures | |||
Value | Approx. Sig. | ||
Nominal by Nominal | Phi | .343 | .037 |
Cramer's V | .243 | .037 | |
N of Valid Cases | 114 |
The strength of association between type of anti-ulcer drugs prescribed and their opinions on choosing an antiulcer drug from the following options in price factors is 0.243.
GRAPH 4: RESPONDENT'S OPINION ON PRICE AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Type of anti-ulcer drugs prescribed and distribution factors:
H0: There is no significant association between type of anti-ulcer drugs prescribed and distribution
H1: There is a significant association between type of anti-ulcer drugs prescribed and distribution.
TABLE 5: RESPONDENT'S OPINION ON THE TYPE OF ANTI-ULCER DRUG PRESCRIBED AND DISTRIBUTION
Crosstab | ||||||||||
Opinions of prescribing an anti-ulcer drug based on distribution factors | Total | |||||||||
Disagree | Neutral | Agree | Strongly Disagree | |||||||
Type of anti-ulcer drugs prescribed | Branded | Count | 1 | 19 | 43 | 8 | 71 | |||
% within Type of anti-ulcer drugs prescribed | 1.4% | 26.8% | 60.6% | 11.3% | 100.0% | |||||
Branded Generic | Count | 0 | 5 | 20 | 4 | 29 | ||||
% within Type of anti-ulcer drugs prescribed | .0% | 17.2% | 69.0% | 13.8% | 100.0% | |||||
Generic | Count | 0 | 6 | 6 | 1 | 13 | ||||
% within Type of anti-ulcer drugs prescribed | .0% | 46.2% | 46.2% | 7.7% | 100.0% | |||||
Total | Count | 1 | 30 | 69 | 13 | 113 | ||||
% within Type of anti-ulcer drugs prescribed | .9% | 26.5% | 61.1% | 11.5% | 100.0% | |||||
Chi-Square Tests | ||||||||||
Value | df | Asymp. Sig. (2-sided) | ||||||||
Pearson Chi-Square | 4.494a | 6 | .610 | |||||||
a. 6 cells (50.0%) have expected count less than 5. The minimum expected count is .12. | ||||||||||
From the above table chi square is not significant (sig. value is 0.610 which is greater than 0.05), no evidence to reject null hypothesis. It means that there is no significant association between type of anti-ulcer drugs prescribed and their opinions on choosing anti-ulcer drugs from the following options in distribution factors.
Symmetric Measures | |||
Value | Approx. Sig. | ||
Nominal by Nominal | Phi | .199 | .610 |
Cramer's V | .141 | .610 | |
N of Valid Cases | 113 |
The strength of association between type of anti-ulcer drugs prescribed and their opinions on choosing anti-ulcer drugs from the following options in distribution factors is 0.141
GRAPH 5: RESPONDENT'S OPINION ON THE TYPE OF ANTI-ULCER DRUG PRESCRIBED AND DISTRIBUTION
Type of anti-ulcer drugs prescribed and promotional inputs with respect to anti-ulcer drugs: H0: There is no significant association between type of anti-ulcer drugs prescribed and promotion inputs H1: There is a significant association between type of anti-ulcer drugs prescribed and promotion inputs.
TABLE 6: RESPONDENT'S OPINION ON PROMOTION INPUTS AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Crosstab | |||||||
feel about company’s promotional inputs with respect to anti-ulcer drugs | Total | ||||||
Disagree | Neutral | Agree | Strongly Disagree | ||||
Type of anti-ulcer drugs prescribed | Branded | Count | 9 | 31 | 27 | 4 | 71 |
% within Type of anti-ulcer drugs prescribed | 12.7% | 43.7% | 38.0% | 5.6% | 100.0% | ||
Branded Generic | Count | 4 | 8 | 14 | 3 | 29 | |
% within Type of anti-ulcer drugs prescribed | 13.8% | 27.6% | 48.3% | 10.3% | 100.0% | ||
Generic | Count | 3 | 6 | 3 | 1 | 13 | |
% within Type of anti-ulcer drugs prescribed | 23.1% | 46.2% | 23.1% | 7.7% | 100.0% | ||
Total | Count | 16 | 45 | 44 | 8 | 113 | |
% within Type of anti-ulcer drugs prescribed | 14.2% | 39.8% | 38.9% | 7.1% | 100.0 |
Chi-Square Tests | |||
Value | df | Asymp. Sig. (2-sided) | |
Pearson Chi-Square | 4.485a | 6 | .611 |
a. 4 cells (33.3%) have expected count less than 5. The minimum expected count is .92. |
From the above table chi square is not significant (sig. value is 0.611 which is greater than 0.05), no evidence to reject null hypothesis. It means that there is no significant association between type of anti-ulcer drugs prescribed and their opinions on feel about company’s promotional inputs with respect to anti-ulcer drugs.
Symmetric Measures | |||
Value | Approx. Sig. | ||
Nominal by Nominal | Phi | .199 | .611 |
Cramer's V | .141 | .611 | |
N of Valid Cases | 113 | The strength of association between type of anti-ulcer drugs prescribed and their opinions on feel about company’s promotional inputs with respect to anti-ulcer drugs is 0.141. |
GRAPH 6: RESPONDENT'S OPINION ON PROMOTION INPUTS AND THE TYPE OF ANTI-ULCER DRUG PRESCRIBED
Null Hypotheses | Sig. Value | Result | Strength of
Association (%) |
H0: There is no significant association between type of anti-ulcer drugs prescribed and the quality of ingredient | 0.109 | Rejected | 18.3 |
H0: There is no significant association between type of anti-ulcer drugs prescribed and product name | 0.179 | Rejected | 19.8 |
H0: There is no significant association between type of anti-ulcer drugs prescribed and product attribute factors. | 0.002 | Accepted | 28.4 |
H0: There is no significant association between type of anti-ulcer drugs prescribed and their opinions on choosing an antiulcer drug from the following options in price factors | 0.037 | Accepted | 24.3 |
H0: There is no significant association between type of anti-ulcer drugs prescribed and distribution | 0.610 | Rejected | 14.1 |
H0: There is no significant association between type of anti-ulcer drugs prescribed and promotion inputs | 0.611 | Rejected | 14.1 |
CONCLUSION: The results are giving the important attributes which doctors and pharmacists are looking for. Product attributes and Price have come out to be important elements in prescribing drugs to patients with reference to anti-ulcer drugs. Pharmaceutical companies are giving lot of efforts in making good medicines. They still need to come up with more advancement during the stages of drug development. So, they can come up with drugs that have better safety and efficacy as well with fewer side effects. The results also revealed that Pharmaceutical companies need to come up with new pricing strategies to sustain the competition as the end-users are looking forward for pricing while prescribing drugs to the patients.
REFERENCES:
- Chitta Venkateswara Rao, K. Venkataramaba. A Pharmacological review on natural ulcer agents. Journal of global trends in para-medical sciences.2013;4(3):1118-1131.
- Rakesh Pahwa et al. Clinical Manifestations, Causes and Management Strategies of Peptic Ulcer Disease. International journal of pharmaceutical sciences research. 2010; 2(2):99-106.
- Effectiveness of Lifecycle education in peptic -ulcer patient. World journal of para medical research. 2014; 3(2): 2880-2887.
- Sharma SK et.al. Hospital based analytical study of peptic ulcer disease in patients with dyspeptic symptoms. Katmandu University medical journal.2009; 2(26): 135-138.
- http://www.emedicinehealth.com/peptic_ulcers/page2_em.htm#what_causes_peptic_ulcers
- Anant Patil, Viraj Rajadhyaksha .Evolving role of pharmaceutical physicians in the industry Indian perspective .Perspectives in clinical research.2012; 3(1):35-39.
- Vishnu Prakash Mishra, Rohit Kumar Vishwakarma. Changing Landscape in Marketing Strategies of Indian Pharmaceutical Industry.2014; SSIJMAR: 2(6), 1-10.
- A. Alkhateed. Characteristics of Physicians Targeted by the Pharmaceutical Industry to Participate in E-detailing. Health marketing quarterly.2014; 26: 98-116.
- Francilin J Carter, Ravindra Chitturi. Segmentation based on physician behavior implications for sales forecasting and marketing-mix strategy .Journal of Personal Selling and Sales management.2009; 29(1): 81-95.
- Irfan Sharfoddin Inamdar, Dr. Malhar Jayant Kolhatkar. Doctor’s expectations from pharmaceutical products (medicine) which will influence their prescription behaviour. Abinav journal of research in commerce and management.2013; 1(4):14-20.
- Kothari C.R. Research Methodology Methods and Techniques. New Age international publisher.2009 New Delhi.
- Kotler, P., and Keller, K. L., 2012, Marketing Management, Prentice Hall.
- Indian Pharmaceuticals Industry Analysis” [Online]. Available: http:// www. ibef. org/ industry/indian-pharmaceuticals-industry-analysis-presentation Accessed: 27-Nov-2015]
- “Pharmaceutical marketing,” Wikipedia, the free encyclopedia. “Official website of Department of Pharmaceuticals | National Portal of India” [Online]. Available: http://india.gov.in/official-website-department-pharmaceuticals. [Accessed: 28-Nov-2015].
How to cite this article:
Anusha K, Rao VN and Kumar PV: Marketing of Anti-Ulcer Drugs To the End-Users . Int J Pharm Sci Res 2016; 7(7): 3130-39.doi: 10.13040/IJPSR.0975-8232.7(7).3130-39.
All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Article Information
49
3130-39
545
1147
English
IJPSR
Kanagala Anusha *, V Narasimha Rao and P. Vijaya Kumar
Head of Centre Pharmaceuticals Sciences, Jawaharlal Nehru Technological University, Hyderabad, Telagana, India.
kanagalanusha@gmail.com
21 February, 2016
11 May, 2016
15 May, 2016
10.13040/IJPSR.0975-8232.7(7).3130-39
01 July 2016